Gerald E. Marti - Concepedia

Author

Gerald E. Marti

Also Known As

G E Marti, G E. Marti, G Edward Marti, G Edward W. Marti, G Marti, G Martí, G. E. MARTI, G. E. Marti, G. Marti, G.E. Marti

267

Publications

19.6K

Citations

H-Index

123

Concepts

All Affiliations

National Institutes of Health Center for Biologics Evaluation and Research National Cancer Institute United States Food and Drug Administration National Heart Lung and Blood Institute

About

Gerald E. Marti is an author at National Institutes of Health specializing in medicine, immunology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	51	12.4K
2	Health Sciences	12	13	257
3	Engineering	8	8	692
4	Natural Sciences	1	1	17
5	Public Health	1	1	22

Gerald E. Marti

116

Publications

17.7K

Citations

H-Index

Page 1

	Year	Citations
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis, Nature Hematological MalignancyLymphoid NeoplasiaImmunologyDistinct TypesPathology	2000	9.9K
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia Yair Herishanu, Patricia Pérez‐Galán, Delong Liu, Blood	2010	811
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial Mohammed Farooqui, Janet Valdez, Sabrina Martyr, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaTp53 AberrationsSingle-arm TrialMedicine	2014	365
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia Ola Landgren, Maher Albitar, Wanlong Ma, New England Journal of Medicine	2009	362
Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice Elizabeth Raveché, Erica Salerno, Brian J. Scaglione, Blood	2007	280
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib Clare Sun, Xin Tian, Yuh Shan Lee, Blood	2015	218
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study Inhye E. Ahn, Mohammed Farooqui, Xin Tian, Blood	2018	197
Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study Carsten Utoft Niemann, Sarah E. M. Herman, Irina Marić, Clinical Cancer Research	2015	191
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study Sarah E. M. Herman, Carsten Utoft Niemann, Mahfooz Farooqui, Leukemia Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukemiaIbrutinib-induced LymphocytosisMedicine	2014	187
Hematotoxocity among Chinese workers heavily exposed to benzene Nathaniel Rothman, Guilin Li, Mustafa Dosemeci, American Journal of Industrial Medicine	1996	181

Page 1